Downregulation of Gal-3 expression or activity may be a promising therapeutic strategy to restore the BM niche, enhance the response of AML cells to conventional chemotherapeutic drugs, and improve patient outcomes. This evidence concerns the gene LGALS3 and acute myeloid leukemia.